Curriculum Vitae

Personal information

Kaisa Mari Hämäläinen

Work experience

1. Employer: Orion Corporation Orion Pharma
   - Start date: 121996
   - End date: 102003
   - Position: Clinical Study Manager
   - Activities: Clinical development of asthma drugs, Easyhaler, writing protocols, reports, abstracts, manuscripts etc. Taking part in marketing authorization processes,
   - Country: Finland
2. Employer: University of Kuopio, Department of Pharmaceutics
   - Start date: 102003
   - End date: 082005
   - Position: Researcher
   - Activities: TEKES Bioeyes project _ development of implant into the eye
   - Country: Finland
3. Employer: Orion Corporation Orion Pharma
   - Start date: 092005
   - End date: 072010
   - Position: Clinical Pharmacokineticist/Research Scientist
   - Activities: Responsibility of pharmacokinetic issues in proprietary product projects(i.e. central nervous system, oncology and critical care), in the BE_studies and file evaluations
   - Country: Finland
4. Employer: Finnish Medicine Agency
   - Start date: 072010
   - End date:
   - Position: Senior Researcher
   - Activities: Quality assessments/ clinical pharmacokinetic assessments, scientific advices in all procedures
   - Country: Finland

Education and training

1. Subject: University of Kuopio
   - Start date: 081986
   - End date: 031991
   - Qualification: Master of Science in Pharmacy
   - Organisation:
   - Country: Finland
2. Subject: University of Kuopio
   - Start date:
   - End date: 061996
   - Qualification: Licentiate in Pharmacy
   - Organisation:
   - Country: Finland
3. Subject: University of Kuopio
   - Start date: 021992
   - End date: 081996
   - Qualification: Ph.D.(Pharm)
   - Organisation: Dissertation 2000
   - Country: Finland

Additional information

Publications

1. Vanto T, Hämäläinen KM, Vahteristo M, Wille S, Njå F, Hyldebrand N. Comparison of two dry powder inhalers containing budesonide in the treatment of asthma in children. J Aerosol Med 2004, 17:15_24. 2. Toropainen E, Ranta V_P, Vellonen K_S, Palmgren J, Talvitie A, Laavola M, Suhonen P, Hämäläinen KM, Auriola S, Urtti A. Paracellular and passive transcellular permeability in immortalized human corneal epithelial cell culture model. Eur J Pharm Sci 2003, 20:99_106. 3.Tukiainen H, Rytilä P, Hämäläinen KM, Silvasti M, Keski_Karhu J. Safety, tolerability and acceptability of two dry powder inhalers in the administration of budesonide in steroid_treated asthmatic patients. Respir Med 2002, 96:221_9. 4. Hämäläinen KM, Granander M, Toivanen P, Malinen A. Assessment of the systemic effects of budesonide inhaler from Easyhaler® and from Turbuhaler® in healthy male volunteers. Respir Med 2001, 95:863_9. 5. Hämäläinen KM. Lääke_ ja malliaineiden säädelty vapautuminen polymeerimatriiseista ja läpäisevyys silmän sarveis_, side_ ja kovakalvoissa. Dosis 2000, 16:230_3. 6. Hämäläinen KM, Malinen A, Granander M, Toivanen P, Silvasti M. Assessment of the systemic effects of beclomethasone dipropionate inhaled via Easyhaler or via Diskhaler in healthy male volunteers. Eur J Clin Pharmacol 2000, 56:625_9. 7. Randell J, Hämäläinen KM, Leinonen M, Keski_Karhu J, Silvasti M, Tukiainen H. Salbutamol via Easyhaler® multidose dry powder inhaler produces equivalent relief of histamine_induced bronchoconstriction to salbutamol via pressurised metered_dose inhaler. Clin Drug Invest 2000, 19:2_7. 8. Hämäläinen KM, Ranta V_P, Auriola S and Urtti A. Enzymatic and permeation barrier of D_[Ala2]_Met_enkephalinamide in the anterior membranes of the albino rabbit eye. Eur J Pharm Sci 2000, 9:265_70. 9. Haahtela T, Ahonen A, Hämäläinen K M, Laurikainen K, Kainulainen P , Silvasti M. Histamine_induced bronchoconstriction is equally relieved by Easyhaler® and Diskhaler® salbutamol powder inhalers. Clin Drug Invest 1998, 16, 371_6. 10. Ranta V_P, Hämäläinen KM, Auriola S, Urtti A. Gradient high_performance liquid chromatographic analysis of enkephalin peptides, their metabolites, and enzyme inhibitors

using combined ultraviolet and electrochemical detection. II. Application to ocular permeability studies in vitro. J Chromatogr A 1997, 766:85_97. 11. Hämäläinen KM, Määttä E, Piirainen H, Sarkola M, Väisänen A, Ranta V_P and Urtti A: Physicochemical properties of drug and its release from matrices of Gelfoam and monoisopropyl ester of poly(vinyl methyl ether_maleic anhydride). Roles of acid/base nature and molecular weight. J Control Rel 1998, 56:273_83. 12. Hämäläinen KM, Kontturi K, Auriola S, Murtomäki L and Urtti A: Estimation of Pore Size and Pore Density of Biomembranes from Permeability Measurements of Polyethylene Glycols using Effusion_like Approach. J Control Rel 1997, 49:97_104. 13. Hämäläinen KM, Kananen K, Auriola s, Kontturi K and Urtti A: Characterization of Paracellular and Aqueous Penetration Routes in Cornea, Conjunctiva, and Sclera. Invest Ophthalmol Vis Sci 1997, 38: 627_34. 14. Auriola S, Rönkkö K and Urtti A: Determination of poly(ethylene glycol) by high performance liquid chromatography_thermospray mass spectrometry. J Pharm Biomed Anal 1993, 11:1027_32. 15. Finne U, Rönkkö K and Urtti A: Timolol release from matrices of monoesters of poly(vinyl methyl ether_maleic anhydride): Effects of polymer molecular weight and a basic additive. J Pharm Sci 1991, 30:6.

Projects

Memberships

Presentations at Scientific conferences: Vanto T, Hämäläinen KM, Vahteristo M, Wille S, Njå F, Hyldebrand N. Comparison of two dry powder inhalers containing budesonide in the treatment of asthma in children. ERS, Stockholm, Sweden, 14._18.9.2002 (POSTER). Tukiainen H, Hämäläinen KM and Keski_Karhu J. Budesonide 800 µg/day via Easyhaler® is as safe and effective as the same dose of budesonide via Turbuhaler® in adult asthmatics. Lääkepäivät, Helsinki, Finland, 6_10.1.2002 (POSTER). Rytilä P, Hämäläinen KM, Saarelainen P, Haahtela T. The anti_inflammatory effect of budesonide 800 µg/day via Easyhaler® compared with the same dose of budesonide via Turbuhaler® in adults asthmatics. ERS, Berlin, Germany, 22_26.9.2001 (POSTER). Tukiainen H, Hämäläinen KM and Keski_Karhu J. Budesonide 800 µg/day via Easyhaler® is as safe and effective as the same dose of budesonide via Turbuhaler® in adult asthmatics. ERS, Berlin, Germany, 22_26.9.2001 (POSTER). Hämäläinen KM, Malinen A, Granander M and Toivanen P. Budesonide (800 and 1600 µg/day) via Easyhaler® has equivalent systemic activity to the same doses via Turbuhaler®. ERS, Berlin, Germany, 22_26.9.2001 (POSTER). Hämäläinen KM, Malinen A, Granander M, Toivanen P, Silvasti M. Lack of systemic effects of BDP (800 µg/day) via Easyhaler® confirmed using serum cortisol AUC0_20. XL Nordic Lung Congress, Helsinki, Finland, 7_9.6.2001 (POSTER). Hämäläinen KM. Permeation of ocularly applied drugs into the eye. XXXIV Nordic congress of ophthalmology, Reykjavik, Island, 18_21.6.2000 (ORAL PRESENTATION). Hämäläinen KM, Malinen A, Granander M, Toivanen P, Silvasti M: Lack of systemic effects as assessed by serum cortisol AUC0_20h of beclomethasone dipropionate (BDP) at 800 µg daily dose inhaled via Easyhaler. ERS, Madrid, Spain, 9_13.10.1999 (POSTER). Urtti A, Hämäläinen KM, Auriola S and Kontturi K: Paracellular transport. WV Helsinki University Congress of Drug Research, Helsinki, Finland, 10_11.6.1999 (POSTER). Randell JT, Hämäläinen KM, Leinonen M, Silvasti M, Tukiainen H: Comparison of multidose powder inhaler (MDPI) and inhalation aerosol (MDI) in the treatment of histamine_induced bronchoconstriction with 100 µg salbutamol. World Asthma Meeting, Barcelona, Spain, 9_13.12.1998 (POSTER + ORAL PRESENTATION). Hämäläinen KM, Laurikainen K, Leinonen M, Jäger L: Comparison of two multidose powder inhalers (MDPI) in the treatment of asthma with inhaled corticosteroids. ERS annual congress, Geneva, Switzerland, 19_23.9.1998 (POSTER). Haahtela T, Hämäläinen KM, Laurikainen K, Kainulainen P, Silvasti M: Comparison of Easyhaler®, a multidose powder inhaler with Diskhaler® in the treatment of histamine induced bronchoconstriction with salbutamol. EAACI, Birmingham, UK, 21_26.6.1998 (POSTER). Hämäläinen KM, Kontturi K, Auriola S, Murtomäki L and Urtti A: Estimation of pore sizes and porosity in cornea and conjunctiva using effusion_like approach. Third European congress of pharmaceutical sciences, Edinburgh, Scotland, 15_17.9.1996 (POSTER). Ranta V_P, Hämäläinen KM, Auriola S and Urtti A: HPLC analysis of an enkephalin analog, its metabolites and enzyme inhibitors in ocular penetration studies. Kemian päivät, Helsinki, Finland, 14_16.11.1995 (POSTER). Ranta V_P, Hämäläinen KM, Auriola S and Urtti A: HPLC analysis of an enkephalin analog, its metabolites and enzyme inhibitors in ocular penetration studies. Kemian päivät, Helsinki, Finland, 14_16.11.1995 (POSTER). Hämäläinen KM, Piirainen H, Väisänen A and Urtti A: Molecular weight and pH effects on drug release from Gelfoam®_matrices in vitro. XIII Helsinki University Course in Drug Research, Helsinki, Finland, 18_19.5.1995 (ORAL PRESENTATION). Urtti A, Hämäläinen KM and Auriola S: Molecular weight dependence of PEG permeability in cornea, conjunctiva and sclera in vitro, ARVO Conference, Sarasota, FL, May 1994, Invest.Ophthalmol.Vis.Sci. 35/4:4473_25, 1994 (POSTER). Hämäläinen KM, Piirainen H and Urtti A: Release of compounds with different molecular weights from Gelfoam® matrices in vitro. International Symposium on Methods to overcome biological barriers in drug delivery, University of Kuopio, Finland, 26_28.8. 1993 (POSTER). Hämäläinen KM, Kananen K, Auriola S, and Urtti A: The effect of polyethylene glycol molecular weight on corneal and conjunctival penetration. International Symposium on Methods to overcome biological barriers in drug delivery. University of Kuopio, Finland, 26_28.8.1993 (POSTER). Rönkkö KM, Auriola S and Urtti A: Penetration of [D_Ala2]_Met_enkephalinamide and its metabolic products through conjunctiva. XII Helsinki University Course in Drug Research, 17_18.6.1993, abstract book p.90 (POSTER). Auriola S, Rönkkö KM and Urtti A: Analysis of polyethylene glycol with TSP LC_MS, 41st ASMS Conference on Mass Spectrometry and Allied Topics, San Francisco, CA, 30.5._ 4.6.1993 (POSTER). Rönkkö KM and Urtti A: Conjunctival and corneal penetration of hydrophilic drugs with different molecular weights in vitro. ARVO Conference, Sarasota, FL, May 1993, Invest.Ophthalmol.Vis.Sci. vol 34/4, 3820_53, 1993 (POSTER). Finne U, Rönkkö KM and Urtti A: The effects of polymer molecular weight and a basic additive on timolol release from matrices of monoesters of poly(vinyl methyl ether_maleic anhydride). In book: Fysikaalisen farmasian II symposium (ed. P Kahela and V.P. Tanninen), 30.1.1991 p.76 (POSTER). Finne U, Rönkkö KM and Urtti A: Drug release from unbuffered and buffered matrices of propyl, butyl, and hexyl esters of poly(vinyl methyl ether/maleic anhydride) with different molecular weight. First European Symposium on Controlled Drug Delivery, 28_30.3.1990, Leidschendam, The Netherlands, abstract book p. 95_96 (POSTER).

Other Relevant Information